Targeting presynaptic norepinephrine transporter in brown adipose tissue: A novel imaging approach and potential treatment for diabetes and obesity

Synapse

Volumn 67, Issue 2, 2013, Pages 79-93

  Mirbolooki, M Reza ^a   Constantinescu, Cristian C ^a   Pan, Min Liang ^a   Mukherjee, Jogeshwar ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

18F FDG PET; Atomoxetine; Blood glucose; Brown fat

Indexed keywords

ATOMOXETINE; FLUORODEOXYGLUCOSE F 18; GLUCOSE; PROPRANOLOL;

ANIMAL EXPERIMENT; ARTICLE; BROWN ADIPOSE TISSUE; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; THERMOGENESIS; TISSUE METABOLISM;

ADIPOSE TISSUE, BROWN; ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC UPTAKE INHIBITORS; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FLUORODEOXYGLUCOSE F18; MALE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; OBESITY; PROPRANOLOL; PROPYLAMINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84871413072     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21617     Document Type: Article

References (76)

1. Abrahamian H, Hofmann P, Prager R, Toplak H. 2009. Diabetes mellitus and co-morbid depression: Treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group). Neuropsychiatr Dis Treat 5: 261-266.
2. Adler LA, Spencer TJ, Milton DR, Moore RJ, Michelson D. 2005. Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: An interim analysis. J Clin Psychiatry 66: 294-299.
3. Au-Yong IT, Thorn N, Ganatra R, Perkins AC, Symonds ME. 2009. Brown adipose tissue and seasonal variation in humans. Diabetes 58: 2583-2587.
4. Baba S, Jacene HA, Engles JM, Honda H, Wahl RL. 2010. CT Hounsfield units of brown adipose tissue increase with activation: Preclinical and clinical studies. J Nucl Med 51: 246-250.
5. 18F-FDG in brown adipose tissue. J Nucl Med 48: 981-986.
6. Ball MP, Warren KR, Feldman S, McMahon RP, Kelly DL, Buchanan RW. 2011. Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin Schizophr Relat Psychoses 5: 17-25.
7. Bartelt A, Bruns OT, Reimer R, Hohenberg H, Ittrich H, Peldschus K, Kaul MG, Tromsdorf UI, Weller H, Waurisch C, Eychmuller A, Gordts PL, Rinninger F, Bruegelmann K, Freund B, Nielsen P, Merkel M, Heeren J. 2011. Brown adipose tissue activity controls triglyceride clearance. Nat Med 17: 200-205.
8. Bengtsson T, Cannon B, Nedergaard J. 2000. Differential adrenergic regulation of the gene expression of the beta-adrenoceptor subtypes beta1, beta2 and beta3 in brown adipocytes. Biochem J 347(Pt 3): 643-651.
9. Benz MR, Czernin J, Allen-Auerbach MS, Dry SM, Sutthiruangwong P, Spick C, Radu C, Weber WA, Tap WD, Eilber FC. 2012. 3′-Deoxy-3′-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: A pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response. Cancer 118: 3135-3144.
10. Bloom JD, Dutia MD, Johnson BD, Wissner A, Burns MG, Largis EE, Dolan JA, Claus TH. 1992. Disodium (R, R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino] propyl]-1, 3-benzodioxole-2, 2-dicarboxylate (CL-316, 243). A potent beta-adrenergic agonist virtually specific for beta 3 receptors. A promising antidiabetic and antiobesity agent. J Med Chem 35: 3081-3084.
11. Bronnikov G, Bengtsson T, Kramarova L, Golozoubova V, Cannon B, Nedergaard J. 1999. Beta1 to beta3 switch in control of cyclic adenosine monophosphate during brown adipocyte development explains distinct beta-adrenoceptor subtype mediation of proliferation and differentiation. Endocrinology 140: 4185-4197.
12. Burrows RC, Freeman SD, Charlop AW, Wiseman RW, Adamsen TC, Krohn KA, Spence AM. 2004. [18F]-2-fluoro-2-deoxyglucose transport kinetics as a function of extracellular glucose concentration in malignant glioma, fibroblast and macrophage cells in vitro. Nucl Med Biol 31: 1-9.
13. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW. 2002. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27: 699-711.
14. Cannon B, Nedergaard J. 2004. Brown adipose tissue: Function and physiological significance. Physiol Rev 84: 277-359.
15. Cheng WY, Zhu ZH, Ouyang M. 2009. Patterns and characteristics of brown adipose tissue uptake of 18F-FDG positron emission tomograph/computed tomography imaging. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 31: 370-373.
16. Chernogubova E, Cannon B, Bengtsson T. 2004. Norepinephrine increases glucose transport in brown adipocytes via beta3-adrenoceptors through a cAMP, PKA, and PI3-kinase-dependent pathway stimulating conventional and novel PKCs. Endocrinology 145: 269-280.
17. 18F-FDG PET/CT. J Nucl Med 44: 170-176.
18. Constantinescu CC, Mukherjee J. 2009. Performance evaluation of an Inveon PET preclinical scanner. Phys Med Biol 54: 2885-2899.
19. Cypess AM, Chen YC, Sze C, Wang K, English J, Chan O, Holman AR, Tal I, Palmer MR, Kolodny GM, Kahn CR. 2012. Cold but not sympathomimetics activates human brown adipose tissue in vivo. Proc Natl Acad Sci USA 109: 10001-10005.
20. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, Kuo FC, Palmer EL, Tseng YH, Doria A, Kolodny GM, Kahn CR. 2009. Identification and importance of brown adipose tissue in adult humans. N Engl J Med 360: 1509-1517.
21. Dallner OS, Chernogubova E, Brolinson KA, Bengtsson T. 2006. Beta3-adrenergic receptors stimulate glucose uptake in brown adipocytes by two mechanisms independently of glucose transporter 4 translocation. Endocrinology 147: 5730-5739.
22. De Matteis R, Ricquier D, Cinti S. 1998. TH-, NPY-, SP-, and CGRP-immunoreactive nerves in interscapular brown adipose tissue of adult rats acclimated at different temperatures: An immunohistochemical study. J Neurocytol 27: 877-886.
23. Eng J. 2003. Sample size estimation: how many individuals should be studied? Radiology 227: 309-313.
24. Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, Stout D, Phelps ME, Weber WA. 2006. Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med 47: 999-1006.
25. Gadde KM, Yonish GM, Wagner HR, II, Foust MS, Allison DB. 2006. Atomoxetine for weight reduction in obese women: A preliminary randomised controlled trial. Int J Obes 30: 1138-1142.
26. Garnock-Jones KP, Keating GM. 2009. Atomoxetine: A review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs 11: 203-226.
27. Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV. 2011. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 306: 2673-2683.
28. Hamann A, Flier JS, Lowell BB. 1996. Decreased brown fat markedly enhances susceptibility to diet-induced obesity, diabetes, and hyperlipidemia. Endocrinology 137: 21-29.
29. Hildebrandt IJ, Su H, Weber WA. 2008. Anesthesia and other considerations for in vivo imaging of small animals. ILAR J 49: 17-26.
30. Inokuma K, Ogura-Okamatsu Y, Toda C, Kimura K, Yamashita H, Saito M. 2005. Uncoupling protein 1 is necessary for norepinephrine-induced glucose utilization in brown adipose tissue. Diabetes 54: 1385-1391.
31. Iyer RB, Guo CC, Perrier N. 2009. Adrenal pheochromocytoma with surrounding brown fat stimulation. AJR 192: 300-301.
32. Jacene HA, Cohade CC, Zhang Z, Wahl RL. 2011. The relationship between patients' serum glucose levels and metabolically active brown adipose tissue detected by PET/CT. Mol Imaging Biol 13: 1278-1283.
33. Jensen MD, Haymond MW, Gerich JE, Cryer PE, Miles JM. 1987. Lipolysis during fasting. Decreased suppression by insulin and increased stimulation by epinephrine. J Clin Investig 79: 207-213.
34. Kim S, Krynyckyi BR, Machac J, Kim CK. 2008. Temporal relation between temperature change and FDG uptake in brown adipose tissue. Eur J Nucl Med Mol Imaging 35: 984-989.
35. Kim YW, Shin JC, An YS. 2010. Treatment of chronic akinetic mutism with atomoxetine: subtraction analysis of brain f-18 fluorodeoxyglucose positron emission tomographic images before and after medication: A case report. Clin Neuropharmacol 33: 209-211.
36. Lachance J, Page E. 1953. Hormonal factors influencing fat deposition in the interscapular brown adipose tissue of the white rat. Endocrinology 52: 57-64.
37. Lafontan M, Berlan M. 1993. Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res 34: 1057-1091.
38. Ledbetter M. 2006. Atomoxetine: A novel treatment for child and adult ADHD. Neuropsychiatr Dis Treat 2: 455-466.
39. Lee KH, Ko BH, Paik JY, Jung KH, Choe YS, Choi Y, Kim BT. 2005. Effects of anesthetic agents and fasting duration on 18F-FDG biodistribution and insulin levels in tumor-bearing mice. JNucl Med 46: 1531-1536.
40. Letovanec I, Allenbach G, Mihaescu A, Nicod Lalonde M, Schmidt S, Stupp R, Fitting JW, Boubaker A, Ris HB, Prior JO. 2012. 18F-fluorodeoxyglucose PET/CT findings in pleural effusions of patients with known cancer. A cytopathological correlation. Nuklearmedizin 51:186-193.
41. Lin SF, Fan X, Yeckel CW, Weinzimmer D, Mulnix T, Gallezot JD, Carson RE, Sherwin RS, Ding YS. 2012. Ex vivo and in vivo Evaluation of the norepinephrine transporter ligand [(11)C]MRB for brown adipose tissue imaging. Nucl Med Biol. 39: 1081-1086.
42. Liu X, Perusse F, Bukowiecki LJ. 1998. Mechanisms of the antidiabetic effects of the beta 3-adrenergic agonist CL-316 243 in obese Zucker-ZDF rats. Am J Physiol 274(5 Pt 2): R1212-R1219.
43. Ma SW, Foster DO. 1986. Uptake of glucose and release of fatty acids and glycerol by rat brown adipose tissue in vivo. Can J Physiol Pharmacol 64: 609-614.
44. Marette A, Bukowiecki LJ. 1991. Noradrenaline stimulates glucose transport in rat brown adipocytes by activating thermogenesis. Evidence that fatty acid activation of mitochondrial respiration enhances glucose transport. Biochem J 277(Pt 1): 119-124.
45. Marnane M, Merwick A, Sheehan OC, Hannon N, Foran P, Grant T, Dolan E, Moroney J, Murphy S, O'Rourke K, O'Malley K, O'Donohoe M, McDonnell C, Noone I, Barry M, Crowe M, Kavanagh E, O'Connell M, Kelly PJ. 2012. Carotid plaque inflammation on 18F-fluorodeoxyglucose positron emission tomography predicts early stroke recurrence. Ann Neurol 71: 709-718.
46. Mattsson CL, Csikasz RI, Chernogubova E, Yamamoto DL, Hogberg HT, Amri EZ, Hutchinson DS, Bengtsson T. 2011. Beta(1)-adrenergic receptors increase UCP1 in human MADS brown adipocytes and rescue cold-acclimated beta(3)-adrenergic receptor-knockout mice via nonshivering thermogenesis. Am J Physiol 301: E1108-E1118.
47. McElroy SL, Guerdjikova A, Kotwal R, Welge JA, Nelson EB, Lake KA, Keck PE, Jr., Hudson JI. 2007. Atomoxetine in the treatment of binge-eating disorder: A randomized placebo-controlled trial. J Clin Psychiatry 68: 390-398.
48. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke J, Dietrich A, Milton D. 2003. Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biol Psychiatry 53: 112-120.
49. Mirbolooki MR, Constantinescu CC, Pan ML, Mukherjee J. 2011. Quantitative assessment of brown adipose tissue metabolic activity and volume using 18F-FDG PET/CT and β3-adrenergic receptor activation. EJNMMI Res 1: 30.
50. Mizuma H, Shukuri M, Hayashi T, Watanabe Y, Onoe H. 2010. Establishment of in vivo brain imaging method in conscious mice. J Nucl Med 51: 1068-1075.
51. Mukherjee J, Yang ZY, Lew R, Brown T, Kronmal S, Cooper MD, Seiden LS. 1997. Evaluation of d-amphetamine effects on the binding of dopamine D-2 receptor radioligand, 18F-fallypride in nonhuman primates using positron emission tomography. Synapse (New York, NY) 27: 1-13.
52. Nedergaard J, Bengtsson T, Cannon B. 2007. Unexpected evidence for active brown adipose tissue in adult humans. Am J Physiol 293: E444-E452.
53. Nedergaard J, Bengtsson T, Cannon B. 2010. Three years with adult human brown adipose tissue. Ann N Y Acad Sci 1212: E20-E36.
54. Nedergaard J, Bengtsson T, Cannon B. 2011. New powers of brown fat: Fighting the metabolic syndrome. Cell Metab 13: 238-240.
55. Pfannenberg C, Werner MK, Ripkens S, Stef I, Deckert A, Schmadl M, Reimold M, Haring HU, Claussen CD, Stefan N. 2010. Impact of age on the relationships of brown adipose tissue with sex and adiposity in humans. Diabetes 59: 1789-1793.
56. Postic C, Leturque A, Printz RL, Maulard P, Loizeau M, Granner DK, Girard J. 1994. Development and regulation of glucose transporter and hexokinase expression in rat. Am J Physiol 266(4 Pt 1): E548-E559.
57. Quevedo S, Roca P, Pico C, Palou A. 1998. Sex-associated differences in cold-induced UCP1 synthesis in rodent brown adipose tissue. Pflugers Arch 436: 689-695.
58. Roe K, Aleksandersen TB, Kristian A, Nilsen LB, Seierstad T, Qu H, Ree AH, Olsen DR, Malinen E. 2010. Preclinical dynamic 18F-FDG PET: Tumor characterization and radiotherapy response assessment by kinetic compartment analysis. Acta Oncol (Stockholm, Sweden) 49: 914-921.
59. Rosler M, Casas M, Konofal E, Buitelaar J. 2010. Attention deficit hyperactivity disorder in adults. World J Biol Psychiatry 11: 684-698.
60. Saito M, Okamatsu-Ogura Y, Matsushita M, Watanabe K, Yoneshiro T, Nio-Kobayashi J, Iwanaga T, Miyagawa M, Kameya T, Nakada K, Kawai Y, Tsujisaki M. 2009. High incidence of metabolically active brown adipose tissue in healthy adult humans: Effects of cold exposure and adiposity. Diabetes 58: 1526-1531.
61. Santalucia T, Camps M, Castello A, Munoz P, Nuel A, Testar X, Palacin M, Zorzano A. 1992. Developmental regulation of GLUT-1 (erythroid/Hep G2) and GLUT-4 (muscle/fat) glucose transporter expression in rat heart, skeletal muscle, and brown adipose tissue. Endocrinology 130: 837-846.
62. Sauer JM, Ring BJ, Witcher JW. 2005. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet 44: 571-590.
63. Scheen AJ. 2010. Cardiovascular risk-benefit profile of sibutramine. Am J Cardiovasc Drugs 10: 321-334.
64. Scherer D, Hassel D, Bloehs R, Zitron E, von Lowenstern K, Seyler C, Thomas D, Konrad F, Burgers HF, Seemann G, Rottbauer W, Katus HA, Karle CA, Scholz EP. 2009. Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents. Br J Pharmacol 156: 226-236.
65. Schinagl DA, Span PN, Oyen WJ, Kaanders JH. 2011. Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study. Eur J Nucl Med Mol Imaging 38: 1449-1458.
66. Shimizu Y, Satoh S, Yano H, Minokoshi Y, Cushman SW, Shimazu T. 1998. Effects of noradrenaline on the cell-surface glucose transporters in cultured brown adipocytes: Novel mechanism for selective activation of GLUT1 glucose transporters. Biochem J 330(Pt 1): 397-403.
67. Stefan N, Pfannenberg C, Haring HU. 2009. The importance of brown adipose tissue. N Engl J Med 361: 416-417; author reply 418-421.
68. Symonds ME, Budge H, Perkins AC, Lomax MA. 2011. Adipose tissue development: impact of the early life environment. Prog Biophys Mol Biol 106: 300-306.
69. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, Drossaerts JM, Kemerink GJ, Bouvy ND, Schrauwen P, Teule GJ. 2009. Cold-activated brown adipose tissue in healthy men. N Engl J Med 360: 1500-1508.
70. Vanttinen M, Nuutila P, Kuulasmaa T, Pihlajamaki J, Hallsten K, Virtanen KA, Lautamaki R, Peltoniemi P, Takala T, Viljanen AP, Knuuti J, Laakso M. 2005. Single nucleotide polymorphisms in the peroxisome proliferator-activated receptor delta gene are associated with skeletal muscle glucose uptake. Diabetes 54: 3587-3591.
71. Virtanen KA, Lidell ME, Orava J, Heglind M, Westergren R, Niemi T, Taittonen M, Laine J, Savisto NJ, Enerback S, Nuutila P. 2009. Functional brown adipose tissue in healthy adults. N Engl J Med 360: 1518-1525.
72. Weyer C, Tataranni PA, Snitker S, Danforth E, Jr, Ravussin E. 1998. Increase in insulin action and fat oxidation after treatment with CL 316, 243, a highly selective beta3-adrenoceptor agonist in humans. Diabetes 47: 1555-1561.
73. Yamaga LY, Thom AF, Wagner J, Baroni RH, Hidal JT, Funari MG. 2008. The effect of catecholamines on the glucose uptake in brown adipose tissue demonstrated by (18)F-FDG PET/CT in a patient with adrenal pheochromocytoma. Eur J Nucl Med Mol Imaging 35: 446-447.
74. Yoneshiro T, Aita S, Matsushita M, Okamatsu-Ogura Y, Kameya T, Kawai Y, Miyagawa M, Tsujisaki M, Saito M. 2011. Age-related decrease in cold-activated brown adipose tissue and accumulation of body fat in healthy humans. Obesity (Silver Spring) 19: 1755-1760.
75. Yoshida T, Sakane N, Wakabayashi Y, Umekawa T, Kondo M. 1994. Anti-obesity and anti-diabetic effects of CL 316, 243, a highly specific beta 3-adrenoceptor agonist, in yellow KK mice. Life Sci 54: 491-498.
76. Zelinka T, Petrak O, Turkova H, Holaj R, Strauch B, Krsek M, Vrankova AB, Musil Z, Duskova J, Kubinyi J, Michalsky D, Novak K, Widimsky J. 2012. High incidence of cardiovascular complications in pheochromocytoma. Horm Metab Res 44: 379-384.